A citation-based method for searching scientific literature

Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan Beeck, Megha Shah, Richard B Warren. Dermatol Ther (Heidelb) 2022
Times Cited: 2







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Luca Mastorino, Sara Susca, Matteo Megna, Niccolò Siliquini, Pietro Quaglino, Michela Ortoncelli, Gianluca Avallone, Marco Rubatto, Gabriella Fabbrocini, Paolo Dapavo,[...]. Dermatol Ther 2022
7
100


Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
121
100

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
290
100

Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
Alessandra Narcisi, Mario Valenti, Andrea Cortese, Francesco Toso, Giulia Pavia, Luigi Gargiulo, Riccardo Borroni, Antonio Costanzo. Dermatol Ther 2022
6
100

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.
Spyridon Gkalpakiotis, Petra Cetkovska, Petr Arenberger, Tomas Dolezal, Monika Arenbergerova, Barbora Velackova, Jorga Fialova, Martina Kojanova. Dermatol Ther (Heidelb) 2021
12
100

Psoriasis and comorbid diseases: Epidemiology.
Junko Takeshita, Sungat Grewal, Sinéad M Langan, Nehal N Mehta, Alexis Ogdie, Abby S Van Voorhees, Joel M Gelfand. J Am Acad Dermatol 2017
426
50

Letter to the editor submitted in response to 'Should the presence of psoriatic arthritis change how we manage psoriasis?'
Matteo Megna, Sonia Sofia Ocampo-Garza, Gabriella Fabbrocini, Luca Potestio. J Dermatolog Treat 2022
1
100

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
April W Armstrong, Luis Puig, Avani Joshi, Martha Skup, David Williams, Junlong Li, Keith A Betts, Matthias Augustin. JAMA Dermatol 2020
83
50

Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
M J Gooderham, K A Papp, C W Lynde. J Eur Acad Dermatol Venereol 2018
49
50

Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
Giulia Radi, Anna Campanati, Federico Diotallevi, Tommaso Bianchelli, Annamaria Offidani. Curr Pharm Biotechnol 2021
16
50

Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi,[...]. Dermatol Ther 2022
5
50

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
James G Krueger, Laura K Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E L Wang, David Hall,[...]. J Allergy Clin Immunol 2015
171
50

Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".
Matteo Megna, Anna Balato, Maddalena Napolitano, Lucia Gallo, Francesco Caso, Luisa Costa, Nicola Balato, Raffaele Scarpa. Clin Rheumatol 2018
34
50


State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
Paolo Gisondi, Davide Geat, Miriam Pizzolato, Giampiero Girolomoni. Curr Opin Pharmacol 2019
22
50

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio,[...]. J Eur Acad Dermatol Venereol 2021
22
50

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
A Ruggiero, G Fabbrocini, E Cinelli, S S Ocampo Garza, E Camela, M Megna. Clin Exp Dermatol 2022
28
50

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.
G Girolomoni, R Strohal, L Puig, H Bachelez, J Barker, W H Boehncke, J C Prinz. J Eur Acad Dermatol Venereol 2017
135
50

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.
Mark G Lebwohl, Ahmed M Soliman, Hongbo Yang, Jessie Wang, Kaitlin Hagan, Byron Padilla, Andreas Pinter. Dermatol Ther (Heidelb) 2022
3
50

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna. J Am Acad Dermatol 2021
24
50


Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
M Napolitano, M Megna, G Fabbrocini, S P Nisticò, N Balato, S Dastoli, C Patruno. Br J Dermatol 2019
25
50


Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.
Marie-Astrid Boutet, Alessandra Nerviani, Gabriele Gallo Afflitto, Costantino Pitzalis. Int J Mol Sci 2018
91
50

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Matthias Augustin, Jo Lambert, Carla Zema, Elizabeth H Z Thompson, Min Yang, Eric Q Wu, Viviana Garcia-Horton, Ziqian Geng, Joaquin M Valdes, Avani Joshi,[...]. JAMA Dermatol 2020
11
50

A case of erythrodermic psoriasis successfully treated with ixekizumab.
Matteo Megna, Lucia Gallo, Nicola Balato, Anna Balato. Dermatol Ther 2019
7
50

Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini. Dermatol Ther 2022
8
50

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.
Matteo Megna, Eleonora Cinelli, Lucia Gallo, Elisa Camela, Angelo Ruggiero, Gabriella Fabbrocini. Arch Dermatol Res 2022
21
50

Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study.
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini. J Dermatolog Treat 2022
13
50

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna. Dermatol Ther 2022
11
50

Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness.
Raquel Rivera-Díaz, Mar LLamas-Velasco, Mercedes Hospital, Isabel Martín, Ofelia Baniandrés, Diana Ruíz-Genao, Pablo de la Cueva, Carmen García-Donoso. Expert Opin Biol Ther 2022
2
50

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Eleonora Cinelli. Dermatol Ther 2021
5
50

Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series.
Noha Mohammed Dawoud, Maha Bedair El Badawy, Hala Subhi Al Eid, Moataz M Abdel Fattah. Indian J Dermatol Venereol Leprol 2022
3
50

Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E et al.
M Megna, L Potestio, L Gallo, G Caiazzo, A Ruggiero, G Fabbrocini. J Eur Acad Dermatol Venereol 2022
30
50

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Matteo Megna, Sonia Sofia Ocampo-Garza, Luca Potestio, Giuseppina Fontanella, Lucia Gallo, Sara Cacciapuoti, Angelo Ruggiero, Gabriella Fabbrocini. Biomedicines 2021
11
50

Switching biologics in psoriasis - practical guidance and evidence to support.
Ya-Chu Tsai, Tsen-Fang Tsai. Expert Rev Clin Pharmacol 2020
16
50


Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Piergiorgio Malagoli, Paolo Dapavo, Giulia Pavia, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo G Carrera, Giovanni Damiani, Valentina Dini,[...]. Dermatol Ther 2022
3
50

Brodalumab: A new way to inhibit IL-17 in psoriasis.
Paola Facheris, Mario Valenti, Giulia Pavia, Elena Guanziroli, Alessandra Narcisi, Riccardo G Borroni, Antonio Costanzo. Dermatol Ther 2020
7
50

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt, Craig L Leonardi, Melinda Gooderham, Kim A Papp, Sandra Philipp, Jashin J Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu,[...]. JAMA Dermatol 2020
64
50

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study.
Luigi Gargiulo, Giulia Pavia, Mario Valenti, Ana Lleo de Nalda, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi. Dermatol Ther (Heidelb) 2022
1
100

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
153
50

A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis.
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio,[...]. J Eur Acad Dermatol Venereol 2022
6
50

Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
Giulia Pavia, Luigi Gargiulo, Andrea Cortese, Mario Valenti, Federica Sanna, Riccardo G Borroni, Antonio Costanzo, Alessandra Narcisi. Dermatol Ther 2022
2
50

Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas.
Dario Kivelevitch, Jillian Frieder, Ian Watson, So Yeon Paek, M Alan Menter. Expert Opin Pharmacother 2018
20
50

Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population.
M Valenti, G Pavia, L Gargiulo, P Facheris, F Sanna, R G Borroni, A Costanzo, A Narcisi. J Dermatolog Treat 2022
7
50


Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis.
Surjit Singh, Saurabh Singh, Abisha Thangaswamy, Pugazhenthan Thangaraju, Shoban Babu Varthya. Dermatol Ther 2021
8
50

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
Riccardo G Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero Di Corteranzo, Alessandra Narcisi, Michela Ortoncelli,[...]. Acta Derm Venereol 2021
12
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.